Oral submucous fibrosis: A review on current treatment approaches
World Journal of Biology Pharmacy and Health Sciences, 13 (2):
157–162 (February 2023)DOI: 10.30574/wjbphs.2023.13.2.0088
Abstract
Oral submucous fibrosis (OSF) is caused by aberrant collagen deposition in the oral mucosa. A chronic, creeping, scarring disease of the oral cavity often involving the pharynx and upper oesophagus is how it's been described for centuries. It is the most dangerous oral premalignant condition and evolve into malignant tumours in 1.5% to 15% of cases. It is found primarily in India, Pakistan, Sri Lanka, and Bangladesh. Submucous fibrosis, ulceration, xerostomia, a burning feeling, and a restricted opening of the mouth are some of the signs and symptoms to look out for. A patient's quality of life is severely affected by all of these factors. Chewing on areca nuts is the most significant source of danger. Efforts to improve management have been ongoing due to the disease's high mortality and high malignant transformation rate, respectively. Understanding the precise involvement of etiological agents in pathogenesis will aid in management and therapy methods. From a molecular standpoint, this paper provides an overview of background of OSF, including its underlying processes, diagnostic biomarkers, and therapy options. Prevention of OSF is just as crucial as rigorous therapy. For future studies to be effective, oral health literacy has to be improved among people at risk for OSF.